

# Federico Pozzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3825780/publications.pdf>

Version: 2024-02-01

40  
papers

565  
citations

623734

14  
h-index

642732

23  
g-index

40  
all docs

40  
docs citations

40  
times ranked

969  
citing authors

#	ARTICLE	IF	CITATIONS
1	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	7.2	74
2	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. <i>Leukemia</i> , 2017, 31, 2407-2415.	7.2	52
3	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	1.4	48
4	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018.	7.2	41
5	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	1.8	34
6	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	1.4	33
7	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- $\kappa$ B pathways. <i>Leukemia</i> , 2018, 32, 654-662.	7.2	31
8	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	7.0	23
9	<i>NOTCH1</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	2.5	22
10	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020, 12, 894.	3.7	22
11	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115.	7.2	21
12	Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	3.5	18
13	COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 712-714.	1.7	17
14	A Simple Multiplex Real-Time PCR Methodology for the SMN1 Gene Copy Number Quantification. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 37-42.	0.7	16
15	Clinical significance of c.7544delCT <i>NOTCH1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	2.5	14
16	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	17.0	14
17	Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. <i>Blood</i> , 2019, 134, 480-480.	1.4	12
18	<i>SF3B1</i> -mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	3.5	12

#	ARTICLE	IF	CITATIONS
19	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	3.5	11
20	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. <i>Leukemia</i> , 2014, 28, 705-708.	7.2	10
21	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353.	3.5	8
22	KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. <i>Cancers</i> , 2022, 14, 666.	3.7	8
23	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296.	1.4	5
24	Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. <i>Cancers</i> , 2022, 14, 2997.	3.7	5
25	<i>ARHGDI3</i> , a mutant <i>TP53</i> -associated Rho GTPase dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	2.5	3
26	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4397-4397.	1.4	3
27	Elastin Microfibril Interfacer1 (EMILIN1) is an alternative prosurvival VLA4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190.	1.7	3
28	Integrin Signaling Shaping BTK-Inhibitor Resistance. <i>Cells</i> , 2022, 11, 2235.	4.1	3
29	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4396-4396.	1.4	2
30	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2870-2870.	1.4	0
31	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1978-1978.	1.4	0
32	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 1718-1718.	1.4	0
33	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.	1.4	0
34	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354.	1.4	0
35	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195.	1.4	0
36	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. <i>Blood</i> , 2018, 132, 944-944.	1.4	0

#	ARTICLE	IF	CITATIONS
37	SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. Blood, 2018, 132, 1838-1838.	1.4	0
38	Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 945-945.	1.4	0
39	KRAS, NRAS and BRAF Mutations Are Highly Enriched in TR12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. Blood, 2018, 132, 3113-3113.	1.4	0
40	Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA). Blood, 2019, 134, 1744-1744.	1.4	0